Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>

Guardado en:

Detalles Bibliográficos
Autor principal:	Monica M. Mita (21585118) (author)
Otros Autores:	Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Publicado:	2025
Materias:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares